Together, these results point to a scenario in which CDK12 overexpression in breast cancer cells, on the one hand, confers resistance to standard genotoxic chemotherapy, while, on the other, it introduces a selective therapeutic vulnerability through pathological rewiring of the SGOC metabolism. Here, CDK12 is linked to breast cancer.